LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

UNH

501.64

+1.75%↑

JNJ

147.85

+1.57%↑

MRK

125.78

+0.49%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

UNH

501.64

+1.75%↑

JNJ

147.85

+1.57%↑

MRK

125.78

+0.49%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

UNH

501.64

+1.75%↑

JNJ

147.85

+1.57%↑

MRK

125.78

+0.49%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

UNH

501.64

+1.75%↑

JNJ

147.85

+1.57%↑

MRK

125.78

+0.49%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

UNH

501.64

+1.75%↑

JNJ

147.85

+1.57%↑

MRK

125.78

+0.49%↑

HomeStock ListAmgen Inc

Amgen Inc

Closed

Sector Healthcare

265.47 -0.04

Overview

Share price change

24h

Current

Min

263.88

Max

266.38

Key metrics

By Trading Economics

Income

-963M

767M

Sales

1.3B

8.2B

P/E

Sector Avg

20.474

23.904

EPS

4.71

Dividend yield

3.838

Profit margin

9.358

Employees

26,700

EBITDA

713M

3.7B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+17.4 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.84%

7.76%

Next Earnings

2 May 2024

Next Dividend date

7 Jun 2024

Next Ex Dividend date

16 May 2024

Market Stats

By TradingEconomics

Market Cap

-5.1B

145B

Previous open

265.51

Previous close

265.47

News Sentiment

By Acuity

29%

71%

57 / 274 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Amgen Inc Chart

Related News

6 Feb 2024, 21:48 UTC

Earnings

Amgen 4Q Revenue Surges as Acquisition Boosts Results

10 Jan 2024, 14:57 UTC

Major Market Movers

Xeris Biopharma Shares Climb 12% on Amgen License Agreement

31 Oct 2023, 14:21 UTC

Earnings

Trending: Amgen's Quarterly Profits Top Street Views

31 Oct 2023, 11:15 UTC

Earnings

Amgen 3Q Profit Sinks On Discontinued Development Charge

11 Apr 2024, 14:46 UTC

Acquisitions, Mergers, Takeovers

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

6 Feb 2024, 21:44 UTC

Earnings

Amgen Rides Nine Record-Making Products To A Fourth-Quarter Sales Beat -- IBD

6 Feb 2024, 21:01 UTC

Earnings

Amgen Sees FY Rev $32.4B-$33.8B >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q EPS $1.42 >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q Net $767M >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide Prolia Sales $1.11B >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide Neulasta Sales $239M >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide XGEVA Sales $527M >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q Rev $8.2B >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen 4Q Adj EPS $4.71 >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen Sees FY EPS $8.42-EPS $9.87 >AMGN

6 Feb 2024, 21:01 UTC

Earnings

Amgen Sees FY Adj EPS $18.90-Adj EPS $20.30 >AMGN

2 Feb 2024, 13:40 UTC

Top News
Earnings

AbbVie Posts Revenue Beat as Humira Sales Tumble. Other Immunology Drugs Are Selling. -- Barrons.com

19 Jan 2024, 10:30 UTC

Top News

Trump and Biden Both Hate Pharma, but Investors Shouldn't -- Heard on the Street -- WSJ

8 Jan 2024, 10:30 UTC

Top News

Investors Hope the Dogs of the Dow Can Find Their Bite -- WSJ

31 Oct 2023, 16:35 UTC

Top News
Earnings

Nevermind Covid, Investors Want a Pfizer Obesity Pill -- Heard on the Street -- WSJ

31 Oct 2023, 13:05 UTC

Earnings

Amgen Boosts Outlook Following Horizon Takeover, But Dips On Light Enbrel Sales -- IBD

31 Oct 2023, 12:04 UTC

Earnings

Amgen Boosts Revenue Guidance. But the Stock Trades Lower. -- Barrons.com

31 Oct 2023, 11:00 UTC

Earnings

Amgen: For Remainder of 2023, Expect Improved Enbrel Coverage Will Lead to Growth in New Patients and Declining Net Selling Price >AMGN

31 Oct 2023, 11:00 UTC

Earnings

Amgen: In Aggregate, Expect Year-Over-Year Net Selling Price and Volume Erosion for Portfolio of Established Products to Continue >AMGN

31 Oct 2023, 11:00 UTC

Earnings

Amgen: Total Sales of Established Products, Including Epogen, Aranesp, Parsabiv and Neulasta, Decreased 30% Year-Over-Year for 3Q, Driven by Lower Net Selling Price and Volume Declines >AMGN

31 Oct 2023, 11:00 UTC

Earnings

Amgen: Year-Over-Year Enbrel Volume Increased 1% in 3Q, Driven by Increase in New Patients Starting Treatment as a Result of Improved Payer Coverage >AMGN

31 Oct 2023, 11:00 UTC

Earnings

Amgen: For Remainder of 2023, Expect Otezla Demand to Continue to Be Affected by These Free Drug Programs >AMGN

31 Oct 2023, 11:00 UTC

Earnings

Amgen: 3Q Product Sales Growth Was Driven by 11% Volume Growth, Partially Offset by 3% Lower Net Selling Price and 3% Unfavorable Changes to Estimated Sales Deductions >AMGN

31 Oct 2023, 11:00 UTC

Earnings

Amgen: Otezla Demand in 3Q Continued to Be Affected by Free Drug Programs for Newly Launched Competition >AMGN

Peer Comparison

Price change

Amgen Inc forecast

Price Target

By TipRanks

17.4% upside

12 Months Forecast

Average 311.72 USD  17.4%

High 380 USD

Low 215 USD

Based on 20 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

10

Buy

8

Hold

2

Sell

Technical Score

By Trading Central

265.08 / 269.95Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

57 / 274 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.